Member Info for Fruitsnveg

Https://www.phc.ox.ac.uk/news/new-study-suggests-antiviral-treatment-course-is-not-long-enough-to-treat-covid-19-in-at-risk-patients

Be aware that it is not a magic bullet, and latest studies (published yesterday) , underline the need for less problematic treatments. The hunt is still on for an antiviral that does not compomise the immune system, as Paxlovid is now shown to do in some patients:

"It potentially means molnupiravir-treated participants would be susceptible to re-infection sooner than the patients who received usual care. "These findings raise important questions about the impact of molnupiravir on patients' immunity," said Dr Oliver van Hecke, Senior Clinical Research Fellow at the University of Oxford and co-author of the study. "Even if taking molnupiravir for longer fully gets rid of the virus, some patients might still develop weaker protection against catching it again in the future. It would be useful to explore whether molnupiravir together with other antiviral drugs in combination better eliminates the virus, and ensures patients build up good immunity against it. This could help prevent treated patients from catching it again soon after and also reduce the chance of passing on mutated viral strains." These findings, say the authors, could help policy makers shape future antiviral treatment strategies and should inform future trials for COVID-19 treatments.

"Conclusion. Inhaled SNG001 upregulated lung antiviral defenses as assessed using sputum cell biomarker responses and accelerated viral clearance, supporting the

proposed mechanism of action as an antiviral treatment for severe viral lung

infections"

Thanks Aether I wasn't aware of that confirmation from AZ. By what do they mean 'TMG'?

Yes I do note AZ history/role here - my response to Spacman was (hopefully) making the point that IMHO Janssen may not be the only rodeo in town. If we do collaborate/partner/whatever, it could be with *any* suitable BP in the respiro space.

I can't see any asset sale being applicable here. This is a spin-out from academia, not a traditional wholly economic start-up. The founders are the originators of the intellectual property, they are still University personnel. Complicated. The Biobank is also an extremely interesting one. You can't just buy and sell human tissue, to my knowledge. If a University spin-out was an animal, I'd be tempted to call it a bit of a protected species....

As for J&J, worth remembering that they are just one possible BP 'interest'. But we don't know for sure who may end up being a partner or collaborator, beyond the Janssen/Synairgen Universal link. Could it end up just as easily being GSK in the frame? Or Sanofi? Or Roche? Or a mix? Or none? Who knows?

Maybe it's just me DocDan but if I were a BP and I was part/fully-funding (or owning, or aiming to acquire) a company that produce such assays, I might also be in the market for another company that use those assays, in order to determine treatment, for a potential blockbuster treatment that they are developing. Dunno. Seems logical to me. Attractive even....

That's not an answer Mani, it's a load of fluffy fluff McFluffystuff (otherwise known as gibberish). IMHO!

Let's have some figures then, just a guesstimate for the potential global market will do.

Be careful there Tommy, you're making a very convincing business case for SNG001!!

Mani(facturo), As for your "lesson in manufacturing", .... who knew SNG will never be commercial"? Tell me, is that why you invested here? LOL.

So what are your figures Mani? How do you arrive that that conclusion? How many units do you see being needed of SNG001, to meet the urgent need for the treatment of severe viral lung infections globally. Hundreds? Thousands? hundreds of thousands? Millions? Tens of millions? What data are you working off for your costings? Let's be having it. Time to put your money where your mouth is and back up your claims with actual real-life workings.

SO ?

It's hard to believe DocDan and Mani didn't read the AGM report already, but here we are nonetheless. Happy reading both.

Soonbetime,

Everything is relative. You can give a patient a cheap horse pill costing peanuts and he can battle and ultimately die from treatment inefficacy over 4 days, all the while requiring the 24/7 care of a dozen rotating critical illness staff, a bed costing, for example, £600 per 24 hour period not unheard of and probably on the cheap side!), not to mention the economic and human toll this causes. I would say that is a very "expensive" and incredibly wasteful strategy in public health practice. Far better to have a drug deemed "expensive" by some (compared to the £5 horse pills) which *actually works*, and gets that patient out of a Critical Care unit, back on a ward, and home as soon as possible. What we know of possible pricing of the drug (which has not been finalised) actually puts it as less expensive than some stand-alone Covid treatments. We know this, it has been analysed and debated here previously. The cost / benefit savings in the hospital setting are very clear. But they have to be examined in the CONTEXT of where and how the drug will be used.

Chin up Doc, it could still be a blockbuster. Who's to say?

Professor Stephen Holgate is one of the authors of the The MRC Framework for the

Development, Design and Analysis of Stratified Medicine Research, overseen by the M4SM Steering Group, which, coincidentally, is also chaired by Professor Stephen Holgate. Busy guy.

So yes, Professor Stephen Holgate is very much involved in the framework Synairgen are using to develop SNG001. Had you othered to read the AGM Report, you'd know that. Go read it.

SH has worked on clean air technology for years - that's why Dyson, they are the manufacturers that enable the monitoring. He's spent a lifetime fighting to ensure no more kids die needlessly of pollution and mould-exacerbated asthma. Shame on you Mani.

The link to Top MD has already been established and discussed, it's not new. They attended the Synairgen AGM in 2022 I believe? I imagine their findings are relevant to Synairgen, but so could those of other companies that are undertaking similar research and producing similar datasets. Top MD is not the only one, although it is probably closest geographically...

And if they are using AI applications in the clinical trials, that will no doubt turbo-charge evidence generation too. Precision medicine (in which AI plays a key role) seems to very much be a strong theme in the first dozen or so pages of the Synairgen 2023 AGM presentation document issued in June. I imagine that was very much by design, and not by accident.

Artful.

It must be Sunday evening ; the 4 uninvested horsemen of the Apocolypse are back to taunt us with their dastardly tales of woe.

In other news, I have it on good authority that RM is indeed well regarded in Respiro BP circles. ...Still waters runneth deep, etc.

Happy Monday all.

You have a lot to learn my dear Prof. Luckily time is on your side.

TFG have hedged their way into a nice comfortable position here. So comfortable, that they may soon no longer require your posting services Costas. Gulp.

..Or maybe you don't need to call them Costas, just lean across the desk with the Olivetti, and have a quiet word. There's a good chap.